Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination.

Trial Profile

Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Fenofibrate (Primary) ; Metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; Fournier Pharma
  • Most Recent Events

    • 23 Aug 2017 Planned number of patients changed from 8 to 100.
    • 25 Feb 2008 Patient numbers amended from 100 to 8.
    • 31 Aug 2007 Status change from in progress to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top